Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/01/25	$33,000,000	Series A	Apollo Labs BOLD Capital Partners Cerberus Ventures Cerity Partners Ventures Colorcon Ventures Mansueto Investments Portal Innovations Safar Partners W.R. Berkley Corporation Woori Venture Partners	undisclosed